IADR Abstract Archives
Oral Phototherapy With Bioptron Med All® and Periosafe®- aMMP-8 Test
Objectives: Periodontal disease is an infection-induced tissue destructive oral inflammation. We tested in a pilot study the effect of orally administrated polarized blue light on periodontitis risk, aMMP-8 levels and dental plaque.
Methods: Ten adult dental patients were given blue light (Bioptron Med All®) into the oral cavity 10 min for 5 consecutive days. Patients did not change their oral habits, i.e., brushing etc. The inflammatory status was recorded by the chairside Periosafe® aMMP-8 oral mouth rinse test [Sorsa et al. Period 2000 (2016), Heikkinen et al. J Periodontol (2016)]. The mouth was held open with Optragate® (Ivoclar, Vivadent) mouth retractor. A blue light filter was used and the distance was kept at 10 cm from the mouth. The aMMP-8 levels and plaque index (PI) were recorded before and after light therapy.
Results: Eight patients showed decreased aMMP-8 levels assessed by the Periosafe® test. Median plaque index decreased significantly (p< 0,05) from 92 % to 69 %.
Conclusions: Orally administrated polarized blue light seems promising in lowering the oral infection and inflammation burden and periodontal disease risk, i.e. aMMP-8 in mouthrinses. The Bioptron Med All ® device does not emit harmful UV- wavelengths, and thus could be used as an adjunctive oral therapy besides the traditional periodontal treatment especially in treating patients with problems in conducting manual oral hygiene procedures. Mouthrinse elevated MMP-8 can conveniently be assessed by Periosafe®- PoC- assay kit.
Methods: Ten adult dental patients were given blue light (Bioptron Med All®) into the oral cavity 10 min for 5 consecutive days. Patients did not change their oral habits, i.e., brushing etc. The inflammatory status was recorded by the chairside Periosafe® aMMP-8 oral mouth rinse test [Sorsa et al. Period 2000 (2016), Heikkinen et al. J Periodontol (2016)]. The mouth was held open with Optragate® (Ivoclar, Vivadent) mouth retractor. A blue light filter was used and the distance was kept at 10 cm from the mouth. The aMMP-8 levels and plaque index (PI) were recorded before and after light therapy.
Results: Eight patients showed decreased aMMP-8 levels assessed by the Periosafe® test. Median plaque index decreased significantly (p< 0,05) from 92 % to 69 %.
Conclusions: Orally administrated polarized blue light seems promising in lowering the oral infection and inflammation burden and periodontal disease risk, i.e. aMMP-8 in mouthrinses. The Bioptron Med All ® device does not emit harmful UV- wavelengths, and thus could be used as an adjunctive oral therapy besides the traditional periodontal treatment especially in treating patients with problems in conducting manual oral hygiene procedures. Mouthrinse elevated MMP-8 can conveniently be assessed by Periosafe®- PoC- assay kit.